Page 2 - Alonza News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Lonza Group AG Key word Forecast Capital Markets Day 2023 New MidTerm Guidance 2024 – 2028 Supported by RampUp of Growth Projects 17Oct2023 0700 CETCEST Release of an ad hoc announcement pursuant to
Lonza said on Tuesday it has capacity to fill syringes to serve makers of highly popular new weight-loss drugs in a class known as GLP-1, though it does not produce the active ingredient in those drugs. The Swiss drug contract manufacturer, which is holding a capital markets day on Tuesday, said it is producing an excipient, the industry term for an ingredient that helps the body to absorb the main active substance, for one GLP-1 drug. "We are not in the drug substance (business) but we have fill and finish capacities now and in the future for this growth business," he added.
Lonza Group AG Key word Forecast Lonza Confirms Details of Capital Markets Day and Reconfirms Outlook 2023 21Sep2023 0700 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issuer is
(Reuters) -Contract drug manufacturer Lonza said on Monday Chief Executive Pierre-Alain Ruffieux will leave the Swiss company by mutual agreement at the end of the month, weighing on investor confidence about the group's medium-term profit prospects. Lonza said its medium-term strategy and outlook would be discussed in detail at its capital markets day on Oct. 17 and that Chairman Albert Baehny would take on the CEO responsibilities until the appointment of a permanent successor to Ruffieux. Shares in Lonza, which makes drug ingredients for healthcare and biotech companies, dropped 5.3% shortly after the 0700 GMT market open, trading near an eight-month low.
Lonza Group AG Key word Personnel Board Announcement 18Sep2023 0700 CETCEST Release of an ad hoc announcement pursuant to Art 53 LR The issuer is solely responsible for the content of this announceme